Contrasting Candel Therapeutics (NASDAQ:CADL) and Genetic Technologies (NASDAQ:GENE)

Candel Therapeutics (NASDAQ:CADL) and Genetic Technologies (NASDAQ:GENE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Valuation and Earnings

This table compares Candel Therapeutics and Genetic Technologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	$120,000.00	2,235.43	-$37.94 million	($1.73)	-4.77
Genetic Technologies	$7.66 million	0.44	-$7.88 million	N/A	N/A

Genetic Technologies has higher revenue and earnings than Candel Therapeutics.

Analyst Ratings

This is a summary of current ratings and target prices for Candel Therapeutics and Genetic Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	0	0	4	0	3.00
Genetic Technologies	0	0	0	0	0.00

Candel Therapeutics currently has a consensus price target of $21.00, indicating a potential upside of 154.24%. Given Candel Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Candel Therapeutics is more favorable than Genetic Technologies.

Insider & Institutional Ownership

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 0.6% of Genetic Technologies shares are held by institutional investors. 41.6% of Candel Therapeutics shares are held by company insiders. Comparatively, 6.5% of Genetic Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Candel Therapeutics and Genetic Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-629.29%	-173.39%
Genetic Technologies	N/A	N/A	N/A

Volatility and Risk

Candel Therapeutics has a beta of -1.29, indicating that its stock price is 229% less volatile than the S&P 500. Comparatively, Genetic Technologies has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

Summary

Candel Therapeutics beats Genetic Technologies on 6 of the 11 factors compared between the two stocks.

About Candel Therapeutics

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

About Genetic Technologies

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.